StockNews.AI
CASI
StockNews.AI
104 days

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement

1. CASI receives notice from Nasdaq for MVLS non-compliance. 2. Company must maintain a market value of $35 million to remain listed.

2m saved
Insight
Article

FAQ

Why Bearish?

Non-compliance may lead to delisting, causing investor uncertainty. Historically, stocks facing delisting notices often experience significant sell-offs.

How important is it?

The MVLS deficiency directly threatens CASI's Nasdaq listing status, influencing investor confidence. Non-compliance needs urgent attention to avoid adverse financial consequences.

Why Short Term?

Immediate market reaction expected due to compliance issues with Nasdaq regulations. Delisting fears can lead to rapid changes in stock prices.

Related Companies

NOGCEMICELZ
BEIJING, CHINA / ACCESS Newswire / May 7, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") dated May 5, 2025 stating that the Company is not in compliance with the requirement to maintain a minimum Market Value of Listed Securities ("MVLS") of $35 million as set forth under Nasdaq Listing Rule for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum MVLS of $35 million (the "MVLS Requirement"), and Nasdaq Listing Rule 5810(c)(3)(C) specifies that a deficiency occurs if the MVLS falls below this threshold for 30 consecutive business days.

Related News